Neurologic Stem Cell Treatment Study

Researchers from the National Institute of Health are completing a new study of Stem Cell treatment for a wide variety of conditions and diseases. The study aims to test the safety and efficacy of using bone marrow derived stem cells from the patient and injecting them/ applying them to the nasal passages in an attempt to improve neurologic function. The first arm of this study is the collection, cultivation, and re-injection of the stem cells while the second arm has an additional treatment of application of the stem cells to the nasal passages. The researchers plan to monitor the patients in order to analyze any improvements in activities of daily living and neurologic functioning. Possible patients include those over 18 years old that are not pregnant, can provide informed medical consent, and suffer from many of the common neurological impairments including: stroke victims, Parkinson’s, ALS, traumatic brain injury, and many other neurodegenerative diseases.



Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People with Parkinson’s (PD)

Researchers at University of Jordan are creating a study for candidates suffering from Parkinson’s Disease in an effort to help treat them while evaluating the safety outcomes and any adverse effects that may come after. This study is a single group assignment in phase 1 and 2. The two arms of the experiment include injecting patients intravenously with the allogenic umbilical cord-derived mesenchymal stem cells, along with an injection of MSC’s differentiated into neural stem cells. The primary outcomes for the researchers are to measure any treatment-related adverse effects. The eligibility of this study includes being 20 years or over, non-smoker, a diagnosis of the condition, and screening to overload any drugs previously used for the condition.



Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson’s Disease

This is a phase 1 trial currently recruiting by Hebei Newtherapy BIo-Pharma technology Co., Ltd. that uses umbilical cord derived mesenchymal stem cells to seek out a treatment option for patients with Parkinson’s. This is a single group assignment with one arm consisting of splitting patients into a therapy group and a control group. The therapy group receives treatment of UC-MSC’s once a week lasting for three weeks. The control group was evaluated with conventional treatment. Both groups were evaluated for up to a year. The primary outcome of this study is to measure changes in the Unified Parkinson’s Disease Rating Scale. Patients must be from 40-60 years old with a diagnosis of Parkinson’s Disease.


Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson’s Disease

The University of Texas Health Science Center completed a study that accesses the safety, feasibility, and efficacy of using allogenic bone marrow- derived mesenchymal stem cells intravenously for patients with Parkinson’s. This study is in phases 1 and 2 and is a single group assignment. The one arm consists of injecting MSC’s in escalating doses for up to 4 doses. Other than the main goals, the researchers also assess the changes in motor function in patients after treatment. There were no results posted after the trial.



0 0 votes